These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

411 related items for PubMed ID: 30802677

  • 21. An NLRP3-specific inflammasome inhibitor attenuates crystal-induced kidney fibrosis in mice.
    Ludwig-Portugall I, Bartok E, Dhana E, Evers BD, Primiano MJ, Hall JP, Franklin BS, Knolle PA, Hornung V, Hartmann G, Boor P, Latz E, Kurts C.
    Kidney Int; 2016 Sep; 90(3):525-39. PubMed ID: 27262364
    [Abstract] [Full Text] [Related]

  • 22. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition.
    Coll RC, Hill JR, Day CJ, Zamoshnikova A, Boucher D, Massey NL, Chitty JL, Fraser JA, Jennings MP, Robertson AAB, Schroder K.
    Nat Chem Biol; 2019 Jun; 15(6):556-559. PubMed ID: 31086327
    [Abstract] [Full Text] [Related]

  • 23. Inhibition of NLRP3 Inflammasome Prevents LPS-Induced Inflammatory Hyperalgesia in Mice: Contribution of NF-κB, Caspase-1/11, ASC, NOX, and NOS Isoforms.
    Dolunay A, Senol SP, Temiz-Resitoglu M, Guden DS, Sari AN, Sahan-Firat S, Tunctan B.
    Inflammation; 2017 Apr; 40(2):366-386. PubMed ID: 27924425
    [Abstract] [Full Text] [Related]

  • 24. Evidence against a role for NLRP3-driven islet inflammation in db/db mice.
    Kammoun HL, Allen TL, Henstridge DC, Barre S, Coll RC, Lancaster GI, Cron L, Reibe S, Chan JY, Bensellam M, Laybutt DR, Butler MS, Robertson AAB, O'Neill LA, Cooper MA, Febbraio MA.
    Mol Metab; 2018 Apr; 10():66-73. PubMed ID: 29478918
    [Abstract] [Full Text] [Related]

  • 25. MCC950 Inhibits NLRP3 Inflammasome and Alleviates Axonal Injures in Early Stages of Diffuse Axonal Injury in Rats.
    Zhao J, Guo X, Wang B, Yang Z, Huang T, Guo D, Zhang M, Song J.
    Neurochem Res; 2020 Sep; 45(9):2020-2031. PubMed ID: 32474832
    [Abstract] [Full Text] [Related]

  • 26. NLRP3 inflammasome activates interleukin-23/interleukin-17 axis during ischaemia-reperfusion injury in cerebral ischaemia in mice.
    Wang H, Zhong D, Chen H, Jin J, Liu Q, Li G.
    Life Sci; 2019 Jun 15; 227():101-113. PubMed ID: 31002919
    [Abstract] [Full Text] [Related]

  • 27. NLRP3 regulates alveolar bone loss in ligature-induced periodontitis by promoting osteoclastic differentiation.
    Chen Y, Yang Q, Lv C, Chen Y, Zhao W, Li W, Chen H, Wang H, Sun W, Yuan H.
    Cell Prolif; 2021 Feb 15; 54(2):e12973. PubMed ID: 33382502
    [Abstract] [Full Text] [Related]

  • 28. Pharmacological inhibition of the NLRP3 inflammasome as a potential target for cancer-induced bone pain.
    Chen SP, Zhou YQ, Wang XM, Sun J, Cao F, HaiSam S, Ye DW, Tian YK.
    Pharmacol Res; 2019 Sep 15; 147():104339. PubMed ID: 31276771
    [Abstract] [Full Text] [Related]

  • 29. The effects of NLRP3 inflammasome inhibition by MCC950 on LPS-induced pancreatic adenocarcinoma inflammation.
    Yaw ACK, Chan EWL, Yap JKY, Mai CW.
    J Cancer Res Clin Oncol; 2020 Sep 15; 146(9):2219-2229. PubMed ID: 32507974
    [Abstract] [Full Text] [Related]

  • 30. MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition.
    Vande Walle L, Stowe IB, Šácha P, Lee BL, Demon D, Fossoul A, Van Hauwermeiren F, Saavedra PHV, Šimon P, Šubrt V, Kostka L, Stivala CE, Pham VC, Staben ST, Yamazoe S, Konvalinka J, Kayagaki N, Lamkanfi M.
    PLoS Biol; 2019 Sep 15; 17(9):e3000354. PubMed ID: 31525186
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Chenodeoxycholic acid activates NLRP3 inflammasome and contributes to cholestatic liver fibrosis.
    Gong Z, Zhou J, Zhao S, Tian C, Wang P, Xu C, Chen Y, Cai W, Wu J.
    Oncotarget; 2016 Dec 20; 7(51):83951-83963. PubMed ID: 27924062
    [Abstract] [Full Text] [Related]

  • 33. MCC950 in the treatment of NLRP3-mediated inflammatory diseases: Latest evidence and therapeutic outcomes.
    Bakhshi S, Shamsi S.
    Int Immunopharmacol; 2022 May 20; 106():108595. PubMed ID: 35124417
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Specific Inhibition of the NLRP3 Inflammasome as an Antiinflammatory Strategy in Cystic Fibrosis.
    McElvaney OJ, Zaslona Z, Becker-Flegler K, Palsson-McDermott EM, Boland F, Gunaratnam C, Gulbins E, O'Neill LA, Reeves EP, McElvaney NG.
    Am J Respir Crit Care Med; 2019 Dec 01; 200(11):1381-1391. PubMed ID: 31454256
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Target of MCC950 in Inhibition of NLRP3 Inflammasome Activation: a Literature Review.
    Wu D, Chen Y, Sun Y, Gao Q, Li H, Yang Z, Wang Y, Jiang X, Yu B.
    Inflammation; 2020 Feb 01; 43(1):17-23. PubMed ID: 31646445
    [Abstract] [Full Text] [Related]

  • 40. Geranylgeranyl diphosphate synthase 1 knockdown suppresses NLRP3 inflammasome activity via promoting autophagy in sepsis-induced acute lung injury.
    Li D, Li C, Wang T, Zhang C, Zhu Z, Zhang G, Fang B.
    Int Immunopharmacol; 2021 Nov 01; 100():108106. PubMed ID: 34530204
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.